Circulation, Vol 55, 785-791, Copyright © 1977 by American Heart Association
AH Gradman, RA Winkle, JW Fitzgerald, PJ Meffin, J Stoner 3d, PA Bell and DC Harrison
The antiarrhythmic action of the beta-blocking drug, acebutolol, was
evaluated in patients with frequent premature ventricular contractions
(PVCs). In the 12 hours following administration of a single 300 mg oral
dose, 8 of 10 patients showed a greater than 50% reduction in PVC
frequency, and statistical analysis indicated that PVC reduction persisted
for 10 hours after the single dose. Analysis of plasma concentrations of
acebutolol and an acetyl metabolite indicated that after single oral doses
of plasma concentrations of the metabolite exceed those of unchanged
acebutolol. When patients were studied during periods of 300 mg doses every
8 hours, eight of 11 showed a 70% reduction in PVC frequency, and analysis
showed that the therapeutic effect was present throughout the 24-hour
monitoring period. Acebutolol slowed the heart rate and prolonged the PR
interval without affecting the QT interval. Significant clinical or
laboratory toxicity was not encountered. In the small group studied,
acebutolol was found to be safe and effective for short-term administration
to patients with frequent PVCs and possessed a relatively long duration of
antiarrhythmic action.
ARTICLES
Suppression of premature ventricular contractions by acebutolol
This article has been cited by other articles:
 |
|
 |
|
  P. C. Deedwania Sotalol Is More Powerful Than Propranolol in Suppressing Complex Ventricular Arrhythmias Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 259 - 272. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Speer Schroeder Newer Antiarrhythmic Agents for Patients With Coronary Artery Disease Angiology, January 1, 1978; 29(1): 22 - 32. [PDF]
|
|